ArticleNature medicine2026
Enhanced dynamic risk stratification of smoldering multiple myeloma.
Abstract read
In one paragraph
Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.Nature medicine · 2026Trial
- Dynamic risk stratification in smoldering multiple myeloma: Integrating evolving biomarkers with the 2/20/20 Model.HemaSphere · 2026Article
- Real World Data and Its Impact on the Management of Plasma Cell Dyscrasias.Current hematologic malignancy reports · 2026Review
- Free Light Chain Monomer-Dimer Pattern Analysis as Non-Invasive Tool in Predicting MGUS and SMM Progression.Cancers · 2026Article
- CAR T cells take on precancers.Nature medicine · 2026Article
Corrections and comments
- Update of
Authors and funding
48 authors.
Floris Chabrun *Center for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6871-8711
Daniel E Schwartz *Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3144-7919
Susanna Gentile *Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0002-1274-8177
Elias K Mai *Heidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-6226-1252
Tulika R GuptaCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jacqueline PerryCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
David M Cordas Dos SantosCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9198-8338
Thomas HielscherDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Annika WerlyHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany.
Sophia K SchmidtHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany.
Foteini TheodorakakouNational and Kapodistrian University of Athens, Athens, Greece.
Despina FotiouNational and Kapodistrian University of Athens, Athens, Greece.
Christine Ivy LiacosNational and Kapodistrian University of Athens, Athens, Greece.
Nikolaos KanelliasNational and Kapodistrian University of Athens, Athens, Greece.
Noelia Collado GisbertCancer Center Clinica Universidad de Navarra (CCUN), CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA) CIBER-ONC number CB16/12/00369, Pamplona, Spain.
Esperanza Martin-SanchezCancer Center Clinica Universidad de Navarra (CCUN), CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA) CIBER-ONC number CB16/12/00369, Pamplona, Spain.
Rosalinda TerminiCancer Center Clinica Universidad de Navarra (CCUN), CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA) CIBER-ONC number CB16/12/00369, Pamplona, Spain.
Johannes WaldschmidtDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.ORCID http://orcid.org/0000-0001-5340-1818
Selina J ChavdaDepartment of Haematology, Cancer Institute, University College London, London, UK.
Louise AinleyDepartment of Haematology, Cancer Institute, University College London, London, UK.
Matteo Claudio Da ViàHematology section, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Claudio De MagistrisHematology section, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Loredana PettineHematology section, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Michael A TimonianCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1014-3502
Jean-Baptiste AlbergeCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4218-7294
Vidhi PatelCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Patrick CostelloCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Catherine TobiaCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sally PhanCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jennifer LambCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Maria-Theresa SilverioCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Maya DavisCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Elizabeth K O'DonnellCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Catherine R MarinacCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Omar NadeemCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Niccolo BolliHematology section, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID http://orcid.org/0000-0002-1018-5139
Kwee YongDepartment of Haematology, Cancer Institute, University College London, London, UK.ORCID http://orcid.org/0000-0002-6487-276X
K Martin KortümDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.ORCID http://orcid.org/0000-0002-7011-0286
Hermann EinseleDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.ORCID http://orcid.org/0000-0002-7680-0819
María-Victoria MateosDepartment of Hematology, University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain.ORCID http://orcid.org/0000-0003-2390-1218
Shaji KumarDepartment of Hematology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5392-9284
Jesús F San-MiguelCancer Center Clinica Universidad de Navarra (CCUN), CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA) CIBER-ONC number CB16/12/00369, Pamplona, Spain.ORCID http://orcid.org/0000-0002-9183-4857
Bruno PaivaCancer Center Clinica Universidad de Navarra (CCUN), CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA) CIBER-ONC number CB16/12/00369, Pamplona, Spain.ORCID http://orcid.org/0000-0003-1977-3815
Efstathios KastritisNational and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0001-8191-5832
Meletios A DimopoulosNational and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0001-8990-3254
Marc S RaabHeidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-4181-6922
Lorenzo TrippaDepartement of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA. ltrippa@ds.dfci.harvard.edu.ORCID http://orcid.org/0000-0001-5218-5666
Irene M GhobrialCenter for Early Detection and Interception-Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-7361-3092
Funding
Molecular Prediction of Myeloma Initiation Molecular Prediction of Myeloma InitiationR35CA263817 · NCI · DANA-FARBER CANCER INST · PI Irene M. Ghobrial · 2022 to 2026
$5.1MMolecular prediction of myeloma in African AmericansU01CA271492 · NCI · DANA-FARBER CANCER INST · PI Catherine Marinac · 2022 to 2026
$4.3MDeutsche Forschungsgemeinschaft (German Research Foundation) 525171148EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 817997Fondazione Umberto Veronesi (Umberto Veronesi Foundation) 5693NCI NIH HHS R35 CA263817NCI NIH HHS U01 CA271492U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) R35CA263817U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) U01CA271492
Abstract
Accurate prediction of risk of progression from smoldering multiple myeloma (SMM) to active multiple myeloma (MM) is paramount to individualized early therapeutic strategies with minimum risk of overtreatment. Current risk stratification models do not account for evolving biomarker trajectories. We assembled a cohort of 2,344 patients with SMM from seven international centers with longitudinal clinical and biological data to train and validate the Precursor Asymptomatic Neoplasms by Group Effort Analysis (PANGEA)-SMM risk models. Four evolving biomarkers were significantly associated with shorter time to progression: M-protein increase ≥0.2 g dl
Indexed as
Multiple MyelomaSmoldering Multiple MyelomaAgedBiomarkers, TumorCreatinineDisease ProgressionFemaleHemoglobinsHumansImmunoglobulin Light ChainsMaleMiddle AgedMyeloma ProteinsRisk AssessmentRisk FactorsBiomarkers, TumorCreatinineHemoglobinsImmunoglobulin Light ChainsMyeloma Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.